SCHEMBL4597835

SCHEMBL4597835

O=C(O)Cc1cc(-c2ccc(C(F)(F)F)cc2)c(-c2ccc(C(F)(F)F)cc2)c(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.73
PSEN2 P49810 1/20 0.73
APH1B Q8WW43 1/20 0.73
NCSTN Q92542 1/20 0.73
APH1A Q96BI3 1/20 0.73
PSENEN Q9NZ42 1/20 0.73
RXRA P19793 9/20 0.56
RXRG P48443 9/20 0.56
RXRB P28702 8/20 0.56
THRB P10828 1/20 0.53
CYP2C9 P11712 1/20 0.48
PPARD Q03181 3/20 0.46
PTGDR2 Q9Y5Y4 3/20 0.46
PPARA Q07869 1/20 0.46
APP P05067 1/20 0.44
GPR35 Q9HC97 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4597847 0.84 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491483 0.82 RXRA (0.71) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4597785 0.82 PSEN1 (0.78) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2272003 0.80 RXRA (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL31741247 0.80 PTGS1 (0.57) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491624 0.78 RXRA (0.65) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4597365 0.77 PSEN1 (0.80) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4598091 0.77 PSEN1 (0.80) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL267205 0.77 RXRA (0.68) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491335 0.77 RXRA (0.63) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300261-A1 Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease MERCK SHARP & DOHME LTD. (GB) 2008-12-04 US disclosed
EP-1773315-B1 ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (GB) 2008-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300261-A1 Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease PSEN2, PSEN1, NAT1 PSEN1 2/4885PSEN2 1/4885APH1B 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.